<SEC-DOCUMENT>0001062993-18-001920.txt : 20180504
<SEC-HEADER>0001062993-18-001920.hdr.sgml : 20180504
<ACCEPTANCE-DATETIME>20180503192017
ACCESSION NUMBER:		0001062993-18-001920
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		6
CONFORMED PERIOD OF REPORT:	20180427
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180504
DATE AS OF CHANGE:		20180503

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lexaria Bioscience Corp.
		CENTRAL INDEX KEY:			0001348362
		STANDARD INDUSTRIAL CLASSIFICATION:	METAL MINING [1000]
		IRS NUMBER:				202000871
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0831

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52138
		FILM NUMBER:		18805592

	BUSINESS ADDRESS:	
		STREET 1:		156 VALLEYVIEW ROAD
		CITY:			KELOWNA
		STATE:			A1
		ZIP:			V1X 3M4
		BUSINESS PHONE:		250-765-6424

	MAIL ADDRESS:	
		STREET 1:		156 VALLEYVIEW ROAD
		CITY:			KELOWNA
		STATE:			A1
		ZIP:			V1X 3M4

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXARIA CORP.
		DATE OF NAME CHANGE:	20080229

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Lexaria Corp.
		DATE OF NAME CHANGE:	20051229
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
   <TITLE>Lexaria Bioscience Corp. - Form 8-K - Filed by newsfilecorp.com</TITLE>
   <META name="HandheldFriendly" content="true">
</HEAD>

<BODY style="font-size:10pt;">

<HR noshade align="center" width=100% size=3 color="black">
<A name=page_1></A>
<P align=center><B><FONT size=5>UNITED STATES</FONT></B><BR><B><FONT
size=5>SECURITIES AND EXCHANGE COMMISSION</FONT></B><BR>Washington, D.C. 20549
</P>
<P align=center><B><FONT size=5>FORM 8-K </FONT></B></P>
<P align=center><B>CURRENT REPORT </B></P>
<P align=center>Pursuant to Section 13 OR 15(d) of the Securities Exchange Act
of 1934 </P>
<P align=center>Date of Report (Date of earliest event reported) <B><U>April 27,
2018</U></B></P>
<P align=center><B><U><FONT size=5>LEXARIA BIOSCIENCE CORP.</FONT></U></B><B>
</B><BR>(Exact name of registrant as specified in its charter) </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=center><B><U>Nevada </U></B></TD>
    <TD align=center width="33%"><B><U>000-52138 </U></B></TD>
  <TD align=center width="33%"><B><U>20-2000871 </U></B></TD>
  </TR>
  <TR vAlign=top>
    <TD align=center>(State or other jurisdiction of </TD>
    <TD align=center width="33%">(Commission File Number) </TD>
  <TD align=center width="33%">(IRS Employer </TD>
  </TR>
  <TR vAlign=top>
    <TD align=center>incorporation) </TD>
    <TD align=center width="33%">&nbsp; </TD>
  <TD align=center width="33%">Identification No.) </TD>
  </TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=center><B><U>156 Valleyview Road, Kelowna, BC Canada </U></B></TD>
  <TD align=center width="33%" ><B><U>V1X 3M4 </U></B></TD>
  </TR>
  <TR vAlign=top>
    <TD align=center>(Address of principal executive offices) </TD>
  <TD align=center width="33%" >(Zip Code) </TD>
  </TR></TABLE>
<P align=center>Registrant&#146;s telephone number, including area code <B><U>(250)
765-6424</U></B><B> </B></P>
<P align=center><B><U>N/A</U></B><B> </B><BR>(Former name or former address, if
changed since last report.) <BR></P>
<P align=justify>Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:</P>
<P align=justify>[&nbsp;&nbsp; ]&nbsp; Written communications pursuant to Rule
425 under the Securities Act (17 CFR 230.425)<BR>[&nbsp;&nbsp; ]&nbsp;
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a -12)<BR>[&nbsp;&nbsp; ]&nbsp; Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))<BR>[&nbsp;&nbsp;
]&nbsp; Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e -4(c))<BR></P>
<P align=justify>Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b -2
of this chapter). </P>
<P align=right>Emerging growth company [&nbsp;&nbsp; ]</P>
<P align=justify>If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to
Section 13(a) of the Exchange Act. </P>
<P align=right>[&nbsp;&nbsp; ]</P>
<P align=justify><B>Item
1.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Entry into a
Material Definitive Agreement </B></P>
<P align=justify>On April 30, 2018, Lexaria announced a major new licensing
agreement with Nuka Enterprises LLC, maker of 1906 brand cannabis chocolates and
other edible products. The deal renews Nuka&#146;s DehydraTECH<sup>TM</sup> license rights for use in its 1906
brand of cannabis chocolates<i>, </i>recognized for their fast onset times,
efficacy, amazing taste and unique formulations.</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_2></A>
<P align=center>- 2 - </P>
<P align=justify>The comprehensive 10-year agreement provides Nuka and 1906 with
competitive technological advantages, as well as growing revenue streams for
Lexaria. The semi-exclusive deal provides Nuka and 1906 with the immediate
ability to utilize DehydraTECH<SUP>TM</SUP> technology across the US. Initially,
1906 will focus on recreational and adult-use states such as Colorado, Nevada,
California, New Jersey, and Massachusetts. Nuka has also acquired an option to
expand its products and brand to Canada, including through the use of Lexaria&#146;s
existing chocolate and confections contract manufacturer licensee Cannfections
Group Inc.</P>
<P align=justify><B>Item
7.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Regulation FD
Disclosure </B></P>
<P align=justify>A copy of the news release announcing that Lexaria has entered
a Letter of Intent (the &#147;LOI&#148;) with Hill Street Beverage Co. is filed as exhibit
99.1 to this current report and is hereby incorporated by reference.</P>
<P align=justify>A copy of the news release announcing that Lexaria has signed a
major new licensing agreement with Nuka Enterprises LLC, maker of 1906 brand
cannabis chocolates is filed as exhibit 99.2 to this current report and is
hereby incorporated by reference. </P>
<P align=justify><B>Item
9.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Financial
Statements and Exhibits </B></P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD vAlign=top width="10%" bgColor=#eeeeee><a href="exhibit10-1.htm">10.1 </a></TD>
    <TD bgColor=#eeeeee >
      <P align=justify><a href="exhibit10-1.htm">Technology License Agreement dated April 24,
  2018</a></P></TD></TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD >&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top width="10%" bgColor=#eeeeee><a href="exhibit99-1.htm">99.1 </a></TD>
    <TD bgColor=#eeeeee >
      <P align=justify><a href="exhibit99-1.htm">Press Release dated April 27, 2018</a></P></TD></TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD >&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top width="10%" bgColor=#eeeeee><a href="exhibit99-2.htm">99.2 </a></TD>
    <TD bgColor=#eeeeee >
      <P align=justify><a href="exhibit99-2.htm">Press Release dated April 30,
2018</a></P></TD></TR></TABLE>
<P align=center><B>SIGNATURES </B></P>
<P align=justify>Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P>
<P align=justify>&nbsp;</P>
<P align=justify><B>LEXARIA BIOSCIENCE CORP.</B> </P>
<P align=justify>&nbsp;</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left><I>/s/ Chris
      Bunka</I> </TD>
    <TD align=left width="50%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left><B>Chris Bunka</B> </TD>
    <TD align=left width="50%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>CEO, Principal Executive Officer </TD>
    <TD align=left width="50%" >&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="50%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Date:&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;May 3, 2018 </TD>
    <TD align=left width="50%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="50%" >&nbsp;</TD></TR></TABLE><BR>
<HR align=center width="100%" color=black noShade SIZE=5>

</BODY>

</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exhibit10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
   <TITLE>Lexaria Bioscience Corp. - Exhibit 10.1 - Filed by newsfilecorp.com</TITLE>
   <META name="HandheldFriendly" content="true">
</HEAD>

<BODY style="font-size:10pt;">

<HR noshade align="center" width=100% size=3 color="black">
<A name=page_1></A>
<P align=right><B>Exhibit 10.1 </B></P>
<P align=center><B>INTELLECTUAL PROPERTY LICENSE</B><BR><B><FONT
size=4>#2018US05 </FONT></B></P>
<P
align=justify><STRONG>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</STRONG>This document certifies that an Intellectual Property License dated as
of April 24, 2018 has been granted by:</P>
<P align=justify><B>Lexaria Bioscience Corp</B>., a Nevada corporation with
offices at 156 Valleyview Rd, Kelowna, British Columbia, V1X 3M4, Canada
(&#147;<B>Licensor</B>&#148;, &#147;<B>Lexaria</B>&#148;, &#147;<B>us</B>&#148;, &#147;<B>our</B>&#148;,
&#147;<B>we</B>&#148;),</P>
<P align=justify>To: </P>
<P align=justify><B>Nuka Enterprises</B>, LLC, a Delaware<B> </B>limited
liability company with offices at 9690 Dallas St., Henderson, Colorado (together
with its successors and assigns &#147;<B>Nuka</B>&#148;, &#147;<B>Licensee</B>&#148;, &#147;<B>you</B>&#148;,
&#147;<B>your</B>&#148;).</P>
<P align=center><B>RECITALS </B></P>
<P
align=justify><STRONG>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</STRONG>WHEREAS certain capitalized terms not otherwise defined below are
defined in Exhibit &#147;D&#148; herein; </P>
<P
align=justify><STRONG>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</STRONG>WHEREAS, LICENSEE is directly or indirectly through a Partner, as
further defined in section 1(a), engaged in the business of developing,
manufacturing, and selling marijuana-infused products pursuant to licenses
issued by the State of Colorado Department of Revenue Marijuana Enforcement
Division (&#147;<B>MED</B>&#148;), pursuant to regulations promulgated under C.R.S. &#167;
12-43.4 -101 <I>et seq</I>, and the City of Henderson, pursuant to regulations
promulgated thereby and pursuant to licenses issued by the authorities relevant
in each and every geographic location optioned within this Agreement, pursuant
to regulations promulgated thereby; </P>
<P
align=justify><STRONG>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</STRONG>WHEREAS, LICENSOR owns and holds, and will make improvements from time
to time upon, certain intellectual property and technology (&#147;<B>Technology</B>&#148;)
related to, including but not limited to, the development, testing, and
manufacturing process for cannabis-infused and vitamin-infused products, which
Technology is more specifically described in Exhibit A and detailed batch
records and formulation calculation spreadsheets that shall be provided by email
prior to the execution of this License Agreement, by LICENSOR to LICENSEE; </P>
<P
align=justify><STRONG>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</STRONG>WHEREAS, LICENSEE wishes to utilize the Technology (which shall include
any Licensor&#146;s Improvements, as defined below) of LICENSOR, and LICENSOR desires
for LICENSEE to utilize the Technology with cannabis-infused chocolates,
candies, and/or consumable liquids and/or topical skin-care or transdermal
products that will always contain more than 0.3% Tetrahydrocannabinol (THC)
(together, the <B>&#147;End Products&#148;</B>), as further described in Exhibit B and in
Definitions, subject to the terms and conditions set forth herein. Such End
Products shall only be distributed and/or sold by LICENSEE or Partner as defined
in Section 1.a below in compliance with all local and state, licensing
requirements within the state of Colorado in which LICENSEE is permitted by this
Agreement or an addendum to this Agreement to sell or distribute the End
Products (such locations collectively referred to as &#147;<B>Permitted
</B><B>Locations</B>&#148; or &#147;<B>Territory</B>&#148;);</P>
<P
align=justify><STRONG>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</STRONG>WHEREAS, LICENSEE shall not export the End Products from any individual
jurisdiction within the Territory to any other location within or outside of the
Territory without express written permission granted in advance from the
LICENSOR and any relevant local laws or authority and subject to entering a
separate licensing agreement or by addendum to this Agreement, and always
subject to availability among other LICENSOR considerations; </P>
<P
align=justify><STRONG>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</STRONG>NOW, THEREFORE, in consideration of the promises and the respective
covenants and agreements of the parties contained in this Agreement, the Parties
hereto agree as follows: </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_2></A>
<P align=center>- 2 - </P>
<P align=center><B>LICENSE</B> </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD vAlign=top width="5%"><B>1.</B> </TD>
    <TD>
      <P align=justify><B>License of Technology: </B>Subject to certain terms
      and conditions, LICENSOR hereby grants to LICENSEE each of the licenses
      more fully defined in Section 2 below.</P></TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%"><B>a)</B> </TD>
    <TD>
      <P align=justify><B>Non-transferable: </B>The license granted by this
      Section 1 may not be transferred or sublicensed by LICENSEE without
      LICENSOR&#146;s written consent. However, LICENSEE has the right to sublicense
      its license to any entity within the Nuka Group.</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%"><B>b)</B> </TD>
    <TD>
      <P align=justify><B>Other Products: </B>The Parties agree that LICENSEE is
      not limited to production of the End Products defined herein, but that
      LICENSEE may develop, create and test new products that are derived from
      or otherwise incorporate the Technology and such new products are only to
      be distributed and/or sold to Permitted Locations (the &#147;New Products&#148;),
      subject to availability of licenses in the future from
  Lexaria.</P></TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD vAlign=top width="5%"><B>2)</B> </TD>
    <TD>
      <P align=justify><B>Semi-Exclusivity. </B>LICENSEE will have the following
      rights to produce and sell the End Products for ten (10) years in the
      Territory using the Technology licensed pursuant to this
  Agreement.</P></TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%"><B>a)</B> </TD>
    <TD>
      <P align=justify><B><U>In the Territory:</U></B></P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD>
      <P align=justify>Semi-Exclusive rights from the Effective Date until ten
      (10) years after the Effective Date, allowing LICENSEE the ability to
      continue to manufacture and sell the End Products directly or through its
      Partner in the Permitted Locations within the Territory for the balance of
      the term of this Agreement as per Section 4. Semi-Exclusive under this
      Agreement means that LICENSOR will not permit more than five (5) other
      such licensees at any time for the End Products utilizing its Technology
      to be granted within the Territory.</P></TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%"><B>b)</B> </TD>
    <TD>
      <P align=justify><B><U>License Option:</U></B></P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD>
      <P align=justify>Furthermore, during the life of this Agreement, LICENSOR
      will reserve one license in each other State in the United States where
      there is a lawful and regulated adult use or medical cannabis market and
      in the country of Canada for each product line in Exhibit B for the
      benefit of LICENSEE to be semi-exclusive in the case of the End Products,
      to distribute and/or sell End Products in locations compliant with all
      local and state laws applicable therein both at the time of effecting this
      Agreement and as laws evolve in America during the life of this Agreement
      under this option arrangement (the &#147;<B>License Option</B>&#148;).</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD>
      <P align=justify>If it chooses to accept a License Option, LICENSEE shall
      provide thirty (30) calendar days&#146; notice in writing not less than 30 days
      in advance prior to first LICENSEE sales expected in each new Subsequent
      Territory under this License Option. License Fees as per Exhibit C start
      as of first LICENSEE sale in each new Subsequent Territory under this
      License Option. For territories where a final, semi-exclusive license is
      the only remaining license available, LICENSOR shall notify LICENSEE that
      such final license exists and LICENSEE shall have the option of receiving
      the final, semi-exclusive license for each Subsequent Territory under this
      License Option if it accepts the option within sixty (60) days of being
      notified in writing by Licensor. If and only at such time as LICENSEE
      notifies LICENSOR that it wants to sell or cause to sell directly or
      through a Partner, as described in Section 1(a), any End Products
      utilizing the Technology in any or all of the Subsequent Territory
      locations included under this License Option (&#147;<B>Exercise of License
      Option</B>&#148;), then LICENSEE does hereby agree to a license of the
      Technology for each state into which it has exercised the License Option
      that is substantially similar to this Agreement in each Subsequent
      Territory optioned in accordance with this License Option (&#147;<B>Subsequent
      License Agreement</B>&#148;). Each Subsequent License Agreement will have an
      expiration date that matches exactly the expiration date of this Agreement
      (ie: April 2028). All such Subsequent License Agreements entered prior to
      September 1, 2023 shall follow to the greatest extent possible the same
proportionate appropriate Territory License fees and Usage fees of this
Agreement subject to those terms found in Exhibit C below. All such Subsequent
License Agreements entered on or after September 1, 2023 shall be subject to
good faith negotiations to determine appropriate fair market value Territory
License fees and Usage Fees relative to the then-current market conditions.</P></TD></TR></TABLE>
<BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_3></A>
<P align=center>- 3 - </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%"><B>c)</B> </TD>
    <TD>
      <P align=justify><B><U>LICENSOR&#146;s Products: </U></B>LICENSOR shall not be
      prohibited from licensing or similar arrangements with respect to the
      Technology outside of the Territory, subject to the terms of this
      Agreement, including the semi-exclusivity provisions and License Options
      and Product Options. LICENSOR is expressly permitted to utilize its
      Technology on any basis it chooses, at any time, for producing and
      commercializing its own products.</P></TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD vAlign=top width="5%"><B>3)</B> </TD>
    <TD>
      <P align=justify><B>Rights and Obligations Related to the Technology.
      </B>Except as expressly provided in this section or elsewhere in this
      Agreement, neither Party will be deemed by this Agreement to have been
      granted any license or other rights to the other Party&#146;s products,
      information or other intellectual property rights, either expressly or by
      implication, estoppel or otherwise.</P></TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%"><B>a)</B> </TD>
    <TD>
      <P align=justify><B><U>LICENSOR Intellectual Property: </U></B>LICENSOR
      retains full, absolute, and complete rights to all processes covered or
      described in all of its issued patents and its patent applications filed
      prior to the date of this Agreement, and any future continuations,
      continuations in part or divisional applications filed thereto, including
      but not limited to the US Provisional patent applications, US Utility
      patent application, and the International patent application, that
      comprise the Technology (&#147;<B>Licensor IP</B>&#148;), unless LICENSOR allows
      these applications to abandon or lapse, or otherwise fails to protect the
      Technology. Except as expressly provided for in Section 2, nothing in this
      Agreement or in the conduct of the Parties shall be interpreted as
      preventing LICENSOR from granting to any other person a license for use of
      the Technology or from using the Technology in any manner
    whatsoever.</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%"><B>b)</B> </TD>
    <TD>
      <P align=justify><B><U>LICENSEE Intellectual Property</U></B>: Any
      intellectual property resulting solely from LICENSEE&#146;s work, know-how, or
      development that does <I>not </I>include nor rely upon the Technology,
      Licensor IP or jointly owned intellectual property, as described in this
      Agreement, shall be owned by LICENSEE (&#147;<B>Licensee IP</B>&#148;).</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%"><B>c)</B> </TD>
    <TD>
      <P align=justify><B><U>Improvements</U></B>:</P></TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%"><B>i)</B> </TD>
    <TD>
      <P align=justify>LICENSOR Improvements: The entire right and title to the
      Technology, whether or not patentable, and any patent applications or
      patents based thereon, which directly relate to and are not severable from
      LICENSOR IP and which are improvements thereto by LICENSOR, its employees
      or others acting solely on LICENSOR&#146;s behalf shall be owned solely by
      LICENSOR (&#147;Licensor Improvements&#148;).</P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%"><B>ii)</B> </TD>
    <TD>
      <P align=justify>LICENSEE Improvements: Rights and title to improvements
      whether or not patentable, and any patent applications or patents based
      thereon, which directly relate to and are not severable from LICENSOR IP
      and which are improvements thereto by LICENSEE, its employees or its
      Partner, as defined by this Agreement, shall be owned by the LICENSEE
      (&#147;Licensee Improvements&#148;). In respect to such Licensee Improvements,
      LICENSOR grants LICENSEE a license to use the underlying intellectual
      property supporting any such improvement for so long as this Agreement
      remains in effect (including any renewal terms) and LICENSOR agrees to
      negotiate in good faith terms of license renewal after the end of the Term
      of this Agreement and any renewal terms per Section 4a. If LICENSEE
      develops any Licensee Improvements, LICENSEE will promptly provide
      LICENSOR with written notice of such Licensee Improvements to validate
      LICENSEE&#146;S claim to Licensee Improvements. Following receipt of notice of
      such Licensee Improvements, LICENSOR shall have the exclusive option
      during the Term of this Agreement (and any renewal terms) to purchase or
      license from LICENSEE the Licensee Improvements for LICENSOR&#146;s use upon
      mutually agreeable terms and conditions that the parties shall
      negotiate in good faith. Nothing in this Agreement shall be
      interpreted to require LICENSEE to sell or license the Licensee
    Improvements to LICENSOR.</P></TD></TR></TABLE>
<BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_4></A>
<P align=center>- 4 - </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%"><B>iii)</B> </TD>
    <TD>
      <P align=justify>Joint Improvements: Rights and title to the Technology,
      whether or not patentable, and any patent applications or patents based
      thereon, which directly relate to and are not severable from LICENSOR IP
      and which are improvements thereto by both LICENSOR AND LICENSEE shall be
      jointly owned intellectual property by LICENSOR AND LICENSEE.</P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%"><B>iv)</B> </TD>
    <TD>
      <P align=justify><U>Improvements; Assignment. </U>LICENSEE and LICENSOR
      hereby represent that all Partners, employees and other persons acting on
      its behalf in performing its obligations under this Agreement shall be
      obligated under a binding written agreement to assign, or as it shall
      direct, all Joint Improvements that include or rely on the Technology
      conceived or reduced to practice by such Partners, employees or other
      persons acting on its behalf in accordance with this Agreement to the
      benefit of LICENSOR and LICENSEE.</P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%"><B>v)</B> </TD>
    <TD>
      <P align=justify><U>Improvements; Confidential Information</U>. All
      Improvements shall constitute Confidential Information and shall be
      subject to the confidentiality provisions set forth in this
    Agreement.</P></TD></TR></TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%"><B>d)</B> </TD>
    <TD colSpan=2>
      <P align=justify><B><U>Inventions; Reporting</U></B>:</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD vAlign=top width="5%"><B>i)</B> </TD>
    <TD>
      <P align=justify>Upon making any invention that does <I>not </I>include or
      rely upon the Technology LICENSEE has no obligation to share such
      information of invention with LICENSOR nor inform LICENSOR of said
      invention, and LICENSEE retains unrestricted rights and ability to use,
      assign, license, seek patent and other forms of intellectual property
      protection related to said invention. For the avoidance of doubt, any such
      new invention, development, technology, and/or intellectual property
      belongs solely to LICENSEE. Upon making any invention that does or does
      NOT include or rely upon the Technology, LICENSOR has no obligation to
      share such information of invention with LICENSEE nor inform LICENSEE of
      said invention, and LICENSOR retains unrestricted rights and ability to
      use, assign, license, seek patent and other forms of intellectual property
      protection related to said invention.</P></TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%"><B>e)</B> </TD>
    <TD colSpan=2>
      <P align=justify><B><U>Jointly Owned Intellectual Property</U></B>: If any
      patent applications are filed seeking to protect any Joint Improvements
      (&#147;<B>Jointly Owned IP</B>&#148;), each Party shall be named as joint
      inventors.</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD vAlign=top width="5%"><B>i)</B> </TD>
    <TD>
      <P align=justify><U>Prosecution and Maintenance of Jointly Owned
      Patents</U>. The Parties shall cooperate to cause the filing of one or
      more patent applications covering any such Jointly Owned IP. The Parties
      will mutually agree upon which of them shall be responsible for filing,
      prosecution and maintenance of Jointly Owned IP. The expenses of such
      filing, prosecution and maintenance shall be equally shared by the Parties
      unless one of the Parties assigns all of its rights to the other Party.
      Both Parties agree to assist the other Party in enforcing its rights in
      the Jointly Owned IP. The costs of any such assistance or cooperation will
      be borne by the requesting party.</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD vAlign=top width="5%"><B>ii)</B> </TD>
    <TD>
      <P align=justify><U>Jointly Owned IP Rights</U>. LICENSOR grants to
      LICENSEE an exclusive, non-sub-licensable, fully-paid, royalty-free,
      perpetual license to any Jointly Owned IP. Further, LICENSEE grants to
      LICENSOR an exclusive, non-sub-licensable, fully-paid, royalty-free,
      perpetual license to any Jointly Owned IP.</P></TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%"><B>f)</B> </TD>
    <TD>
      <P align=justify><B><U>No Challenge</U></B><B>. </B>LICENSEE expressly
      acknowledges and agrees that all rights in and to the Technology shall
      remain vested in LICENSOR, and LICENSEE shall not assert any rights to the
      Technology except as otherwise provided in this Section 3.</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%"><B>g)</B> </TD>
    <TD>
      <P align=justify><B><U>Notice Requirements</U></B><B>. </B>To the extent
      required by applicable rules and regulations, including those of MED
      related to packaging, LICENSEE agrees that it will include such patent
      notices and other proprietary notices on all End Products or related
      materials that contain any Technology if required by MED or other
      regulators in order to give appropriate notice of all intellectual
      property rights therein or pertaining thereto.</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%"><B>h)</B> </TD>
    <TD>
      <P align=justify><B><U>Quality
Control</U></B><B>.</B></P></TD></TR></TABLE><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_5></A>
<P align=center>- 5 - </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%"><B>i)</B> </TD>
    <TD>
      <P align=justify>LICENSEE agrees to maintain and preserve the quality of
      the Technology, and to use the Technology in good faith and in a manner
      consistent with the uses approved herein.</P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%"><B>ii)</B> </TD>
    <TD>
      <P align=justify>LICENSEE shall (a) ensure that all End Products and
      related materials under the Technology are developed, tested, promoted,
      manufactured and distributed in a professional manner in compliance with
      all generally accepted industry standards, and (b) comply in all material
      respects with any and all laws, rules and regulations that are applicable
      to the development, testing, promotion, manufacture and distribution of
      the End Products and such related materials.</P></TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD vAlign=top width="5%"><B>4)</B> </TD>
    <TD colSpan=2>
      <P align=justify><B>Term and Termination.</B></P></TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%"></TD>
    <TD vAlign=top width="5%"><B>a)</B> </TD>
    <TD>
      <P align=justify><U>Term and Renewal. </U>This Agreement shall take effect
      upon signing by both Parties and shall remain in effect for the shorter of
      either ten (10) years; or, such circumstances as described in Section 4.c.
      At any time after the ninth anniversary, this Agreement may be renewed by
      LICENSEE for an additional five (5) years on terms to be negotiated in
      good faith based on market conditions at the time of renewal by the
      Parties.</P></TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%"></TD>
    <TD vAlign=top width="5%"><B>b)</B> </TD>
    <TD>
      <P align=justify><U>Termination. </U>This Agreement and the licenses
      granted hereunder may be terminated prior to the expiration of the initial
      term or any renewal term of this Agreement as
follows:</P></TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%"><B>i)</B> </TD>
    <TD>
      <P align=justify>This Agreement may be terminated by LICENSOR by written
      notice to LICENSEE upon the occurrence of any of the following: (i)
      failure of LICENSEE to pay any license fees for more than sixty (60) days
      after they become due; (ii) LICENSEE&#146;s violation of the provisions of
      Sections 7 and 8 or LICENSEE&#146;s material breach of any other term of this
      Agreement, which breach is not cured within sixty (60) days after written
      notice of such breach from LICENSOR; (iii) failure of LICENSEE to maintain
      all required licenses and governmental authorizations required for the
      conduct of its business or to comply in all material respects with
      applicable laws; or (iv)LICENSEE ceases operations, makes a general
      assignment for the benefit of creditors, or is the subject of a voluntary
      or involuntary bankruptcy, insolvency or similar proceeding.</P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%"><B>ii)</B> </TD>
    <TD>
      <P align=justify>This Agreement may be terminated by LICENSEE by written
      notice to LICENSOR in the event of material breach by LICENSOR of its
      obligations or representations and warranties under this Agreement, which
      breach is not cured within sixty (60) days after written notice of such
      breach from LICENSEE.</P></TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%"><B>c)</B> </TD>
    <TD>
      <P align=justify><U>Effect of Termination</U>. Except as provided for in
      Section 5, LICENSEE&#146;s payment obligations shall extinguish if this
      Agreement is terminated. If the Agreement expires without any renewal
      thereof, then LICENSEE must immediately cease and desist all utilization
      of the Technology to manufacture, distribute or sell End Products, except
      that it may distribute and sell End Products until all finished goods and
      raw materials inventory as of the date of termination (inventory
      verification required) that pertains to the Technology has been sold. In
      any event, upon the natural future expiration of all pending and issued
      patents as applicable related to the Technology described herein the
      License Agreement shall expire and LICENSEE shall have no further payment
      obligations to LICENSOR.</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD>
      <P align=justify><U>Survivability</U><B>. </B>This agreement in its
      entirety survives and remains in force if either Party is acquired by any
      unknown third party. In the event that either Party negotiates any such
      sale or acquisition, then it shall form a part of any such sale or
      acquisition agreement, that this Agreement remains binding upon the third
      party that is the purchaser or acquirer.</P></TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD vAlign=top width="5%"><B>5)</B> </TD>
    <TD>
      <P align=justify><B>Indemnification.</B></P></TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%"><B>a)</B> </TD>
    <TD>
      <P align=justify>LICENSEE agrees to indemnify LICENSOR and hold LICENSOR
      harmless from and against any and all liabilities, losses and expenses
      arising from (i) LICENSEE&#146;s unauthorized use of the Technology; (ii)
      LICENSEE&#146;s failure to comply with applicable laws or to maintain all
      required licenses and governmental authorizations; (iii) any breach of
      LICENSEE&#146;s representations and warranties set forth herein; and (iv) any liability to
      third parties as a result of LICENSEE&#146;s production, distribution and/or
      sale of End Products, except as to any liability arising out of the proper
  use of the Technology.</P></TD></TR></TABLE>
<BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_6></A>
<P align=center>- 6 - </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%"><B>b)</B> </TD>
    <TD>
      <P align=justify>LICENSOR agrees to indemnify LICENSEE and hold LICENSEE
      harmless from and against any and all liabilities, losses and expenses
      arising from (i) any breach of LICENSOR&#146;s representations and warranties
      set forth herein; and (ii) any claims of infringement raised by third
      parties as to the Technology or Licensed
Patents.</P></TD></TR></TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD vAlign=top width="5%"><B>6)</B> </TD>
    <TD>
      <P align=justify><B>Confidentiality. </B>In addition to the
      Confidentiality Agreement previously entered into by the Parties, at all
      times during the term of this Agreement (including any renewal term) and
      thereafter, LICENSEE will not use or disclose and will otherwise keep
      confidential any trade secrets or proprietary information, including, but
      not limited to the Technology and other intellectual property of LICENSOR
      (collectively, the &#147;<B>Confidential Information</B>&#148;) except to the extent
      required to perform its obligations under this Agreement. Without
      limitation of the foregoing, LICENSEE will hold the Confidential
      Information in confidence and will (a) exercise the same degree of care,
      but no less than a reasonable degree of care, to prevent its disclosure as
      LICENSEE would take to safeguard its own confidential or proprietary
      information, and (b) limit disclosure of Confidential Information,
      including any notes, extracts, analyses or materials that would disclose
      Confidential Information, solely to those of its employees who need to
      know the information for purposes of performing its obligations under this
      Agreement and who agree to keep such information confidential. Upon
      termination of this Agreement, LICENSEE shall immediately return all
      Confidential Information to LICENSOR and LICENSOR shall have the right to
      conduct an on-site audit of the LICENSEE within three (3) business days of
      termination to ensure compliance with the terms of this Agreement, at
      LICENSOR&#146;S expense.</P></TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%"></TD>
    <TD>
      <P align=justify>In addition to the Confidentiality Agreement previously
      entered into by the Parties, at all times during the term of this
      Agreement (including any renewal term) and thereafter, LICENSOR will not
      use or disclose and will otherwise keep confidential any trade secrets or
      proprietary information and other intellectual property of LICENSEE
      (collectively, the &#147;<B>Confidential Information</B>&#148;) except to the extent
      required to perform its obligations under this Agreement. Without
      limitation of the foregoing, LICENSOR will hold the Confidential
      Information in confidence and will (a) exercise the same degree of care,
      but no less than a reasonable degree of care, to prevent its disclosure as
      LICENSOR would take to safeguard its own confidential or proprietary
      information, and (b) limit disclosure of Confidential Information,
      including any notes, extracts, analyses or materials that would disclose
      Confidential Information, solely to those of its employees who need to
      know the information for purposes of performing its obligations under this
      Agreement and who agree to keep such information confidential. Upon
      termination of this Agreement, LICENSEE shall immediately return all
      Confidential Information to LICENSEE within three (3) business days of
      termination to ensure compliance with the terms of this Agreement, at
      LICENSEE&#146;S expense.</P></TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%"><B>a)</B> </TD>
    <TD>
      <P align=justify><U>Limitations. </U>This section does not apply to any
      information that: (a) is already lawfully in the receiving Party's
      possession (unless received pursuant to a nondisclosure agreement); (b) is
      or becomes generally available to the public through no fault of the
      receiving Party; (c) is disclosed to the receiving Party by a third party
      who may transfer or disclose such information without restriction; (d) is
      required to be disclosed by the receiving Party as a matter of law
      (provided that the receiving Party will use all reasonable efforts to
      provide the disclosing Party with prior notice of such disclosure and to
      obtain a protective order therefor, with all costs to be borne by the
      disclosing Party); (e) is disclosed by the receiving Party with the
      disclosing Party's approval; or (f) is independently developed by the
      receiving Party without any use of confidential information. In all cases,
      the receiving Party will use all reasonable efforts to give the disclosing
      Party ten (10) days' prior written notice of any disclosure of information
      under this Agreement. The Parties will
maintain the confidentiality of all confidential and proprietary
      information learned pursuant to this Agreement for a period of ten (10)
    years from the date of termination of this Agreement.</P></TD></TR></TABLE>
<BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_7></A>
<P align=center>- 7 - </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%"><B>b)</B> </TD>
    <TD>
      <P align=justify><U>Saving Provision</U>. The Parties agree and stipulate
      that the agreements contained in this Section are fair and reasonable in
      light of all of the facts and circumstances of their relationship;
      however, the Parties are aware that in certain circumstances courts have
      refused to enforce certain agreements. Therefore, in furtherance of and
      not in derogation of the provisions of the preceding paragraph the parties
      agree that in the event a court should decline to enforce the provisions
      of the preceding paragraph, that paragraph shall be deemed to be modified
      to restrict non-enforcing Party&#146;s rights under this Agreement to the
      maximum extent, in both time and geography, which the court shall find
      enforceable.</P></TD></TR></TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD vAlign=top width="5%"><B>7)</B> </TD>
    <TD>
      <P align=justify><B>Limitation of Liability. </B>EXCEPT TO THE EXTENT
      OTHERWISE EXPRESSLY AGREED TO IN THIS AGREEMENT, NEITHER PARTY SHALL BE
      LIABLE TO THE OTHER PARTY FOR LOST PROFITS OR FOR ANY DIRECT, INDIRECT,
      INCIDENTAL, CONSEQUENTIAL, SPECIAL, PUNITIVE OR EXEMPLARY DAMAGES IN
      CONNECTION WITH THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS
      AGREEMENT, HOWEVER CAUSED, UNDER ANY THEORY OF LIABILITY. THE FOREGOING
      SHALL NOT LIMIT LICENSEE&#146;S LIABILITY FOR UNAUTHORIZED USE BY LICENSEE OF
      LICENSOR&#146;S TECHNOLOGY.</P></TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top width="5%"><B>8)</B> </TD>
    <TD>
      <P align=justify><B>No Warranties. OTHER THAN THE EXPRESS WARRANTIES
      PROVIDED HEREIN,</B></P></TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%"></TD>
    <TD>
      <P align=justify>LICENSOR MAKES NO EXPRESS WARRANTIES OF MERCHANTABILITY
      OR FITNESS OR EFFICACY FOR A PARTICULAR PURPOSE OF THE TECHNOLOGY AND/OR
      ANY END PRODUCTS PRODUCED FROM SAID TECHNOLOGY AND SHALL NOT BE HELD
      LIABLE FOR PROFITABILITY OF TECHNOLOGY AND/OR END PRODUCTS OR HELD LIABLE
      UNDER ANY OTHER THEORY OF LIABILITY.</P></TD></TR></TABLE>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW, THEREFORE, in consideration of the premises
and the mutual promises and conditions hereinafter set forth, and other good and
valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the Parties, do hereby agree. </P>
<P
align=justify><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
IN WITNESS WHEREOF</B>, Lexaria Bioscience Corp has granted this license. </P>
<P align=justify>&nbsp;</P>
<P align=justify><B>&#147;LICENSOR&#148; </B><BR><B>LEXARIA BIOSCIENCE CORP.</B> <BR></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; /s/ Chris Bunka, CEO</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_8></A>
<P align=center><B><U>EXHIBIT A</U></B> </P>
<P align=center><B>TECHNOLOGY </B></P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left ></TD>
    <TD align=left width="95%" >The Technology consists of:
</TD></TR>
  <TR vAlign=top>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="95%" >
      <P align=justify>(1) the following patent applications, patents granted,
      and PCT International Patent Applications; (2) all technical know-how and
      trade secrets in regard to such named patents, including the use,
      manufacture or formulation thereof, that is owned or controlled by
      LICENSOR as of the Effective Date of this Agreement, as well as any future
      continuations, continuations in part or divisional applications filed
      pursuant to the patent applications. (the &#147;<B>Licensed Patents</B>&#148;):
    </P></TD></TR></TABLE>
<P align=justify>U.S. Patent Granted No. 9,474,725 awarded October 27, 2016.
</P>
<P align=justify>U.S. Patent Granted No. 9,839,612 B2 awarded December 12, 2017
</P>
<P align=justify>U.S. Provisional Patent Application No. 62/010,601. </P>
<P align=justify>U.S. Provisional Patent Application No. 62/037,706. </P>
<P align=justify>U.S. Provisional Patent Application No. 62/153,835. </P>
<P align=justify>U.S. Provisional Patent Application No. 62/161,324. </P>
<P align=justify>U.S. Notice of Allowance (March 2018) for Provisional Patent
Application No. 15/225,802. </P>
<P align=justify>U.S. Provisional Patent Application No. 15/225,802. </P>
<P align=justify>U.S. Provisional Patent Application No. 62/264,959. </P>
<P align=justify>U.S. Provisional Patent Application No. 62/264,967. </P>
<P align=justify>U.S. Utility Patent Application No. 14/735,844. </P>
<P align=justify>PCT International Patent Application No. </P>
<P align=justify>PCT/US15/35128. PCT International Patent Application No. </P>
<P align=justify>PCT/US16/64295. PCT International Patent Application No.
PCT/US16/64296. </P>
<P align=justify>National filings thereunder:
<BR>2949369,<BR>201580031524.X,<BR>15806768.6,<BR>201647041745.00 <BR>516371405
<BR></P>
<P align=justify>Australian Patent Granted No. 2015274698 awarded June 15, 2017
</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_9></A>
<P align=center><B><U>EXHIBIT B</U></B> </P>
<P align=center><B>END PRODUCTS and PRODUCT OPTIONS</B> </P>
<DIV>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
borderColor=#000000 cellSpacing=0 cellPadding=3 width="100%" border=1>

  <TR vAlign=top>
    <TD align=left>
      <P align=justify><B>Product Line Name</B> </P></TD>
    <TD align=left width="50%">
      <P align=justify><B>Product Line Description</B> </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>Chocolate Products </P></TD>
    <TD align=left width="50%">
      <P align=justify>Any product that is generally recognized as &#147;chocolates,&#148;
      &#147;chocolate bars,&#148; &#147;chocolate treats (including chocolate baked goods),&#148;
      &#147;chocolate truffles,&#148; &#147;caramels,&#148; &#147;chocolate caramels,&#148; &#147;caramel treats,&#148;
      or primarily composed of a form of chocolate or cocoa, and is infused with
      marijuana oil or equivalent containing more than 0.3% THC. </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>Candies Product Line </P></TD>
    <TD align=left width="50%">
      <P align=justify>All products that are not Chocolates but are generally
      recognized as &#147;candies,&#148; &#147;gummies and jellies,&#148; &#147;suckers,&#148; &#147;hard or rock
      candies,&#148; &#147;jelly beans&#148;, mints and non-chocolate mint products, etc, that
      are primarily made with sugar and/or other sweeteners and not generally
      recognized as a natural food and is infused with marijuana oil or
      equivalent containing more than 0.3% THC. This category excludes pills,
      tablets and capsules that are not primarily made with sugar and/or other
      sweeteners, that are generally recognized as vitamins, supplements,
      medicines, sublingual or rapidly dissolving mouth-melts. This category
      also excludes any solid tablet or form factor meant to dissolve in a food
      product, liquid or beverage for purposes of seasoning, flavoring or
      infusing marijuana oil therein. </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>Consumable Liquids </P></TD>
    <TD align=left width="50%">
      <P align=justify>Any consumable liquid products including, but not limited
      to, cold brew or hot coffee, teas, lemonades, flavored waters, juices,
      protein drinks, sport drinks, cocoa drinks, kombuchas, probiotics, energy
      drinks/shots, vitamin waters, tinctures, essential oils, olive oils,
      flavored concentrates, dressings, honeys and syrups, flavored sprays or
      sauces for consumption by way of ingestion that are infused with marijuana
      oil or equivalent containing more than 0.3% THC. </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>Topical Skin Products </P></TD>
    <TD align=left width="50%">
      <P align=justify>Any cream, oil, salve or similar consumer product
      designed to be delivered to and through human skin that is infused with
      marijuana oil or equivalent containing more than 0.3% THC. </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>Pills, tablets, or additives </P></TD>
    <TD align=left width="50%">
      <P align=justify>Any pills, tablets and capsules that are not primarily
      made with sugar and/or other sweeteners, that are generally recognized as
      vitamins, supplements, medicines, sublingual, or rapidly dissolving
      mouth-melts, that are otherwise compliant with this Agreement. This
      category EXCLUDES any solid tablet or form factor meant to dissolve in a
      food product, liquid or beverage for purposes of seasoning, flavoring, or
      infusing marijuana oil therein. </P></TD></TR></TABLE></DIV><BR>
<HR align=center width="100%" color=black noShade SIZE=5>

</BODY>

</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>exhibit99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
   <TITLE>Lexaria Bioscience Corp. - Exhibit 99.1 - Filed by newsfilecorp.com</TITLE>
   <META name="HandheldFriendly" content="true">
</HEAD>

<BODY style="font-size:10pt;">

<HR noshade align="center" width=100% size=3 color="black">
<A name=page_1></A>
<P align=right><B>Exhibit 99.1 </B></P>
<P align=center><B>Lexaria Announces LOI with Hill Street Beverage Co.
for</B><BR><B>Cannabis Infused Alcohol-Free Beer and Wine </B><BR></P>
<P align=justify>Kelowna, British Columbia &#150; April 27, 2018 &#150; Lexaria Bioscience
Corp. (OTCQX: LXRP) (CSE: LXX) (the &#147;Company&#148; or &#147;Lexaria&#148;), a drug delivery
platform innovator, announces that it has entered a Letter of Intent (the &#147;LOI&#148;)
with Hill Street Beverage Co. to license DehydraTECH<SUP>TM</SUP>, on a semi
exclusive basis to produce a line of cannabis infused alcohol-free beers and
wines for Canadian distribution, following regulatory approval. The LOI is
currently non-binding and is subject to the parties entering into a definitive
binding agreement, which is expected to occur in the latter part of 2018.</P>
<P align=justify>Lexaria has already lab-tested Hill Street&#146;s alcohol-free red
and white wines to formulate CBD wines from multi-spectrum hemp oil, and such
tests show virtually zero unwanted cannabis taste or odour. Although
DehydraTECH&#153; functions well with cannabis isolates and distillates, Lexaria&#146;s
technology particularly excels with multi-spectrum oil inputs for more original
experiences. </P>
<P align=justify>Hill Street CEO Terry Donnelly stated, &#147;Having tasted our wines
after Lexaria&#146;s infusion process, we found all of the complexity and richness of
our beverages remains intact, and virtually indistinguishable when comparing the
infused products to the originals in blind taste and aroma tests. Once we
experienced the end result, the decision to partner with Lexaria became very
easy.&#148;</P>
<P align=justify>Lexaria&#146;s beverage formulation adaptations use patented
technology to act quickly, taste great, and deliver predictable experiences that
dissipate more quickly than many other cannabinoid edible products.</P>
<P align=justify>Current legislation does not permit the manufacture and sale of
cannabis infused products in Canada. Legislation to allow the sale of these
products is projected to occur by the summer of 2019. Hill Street is currently
applying for appropriate licenses to permit the production and sale of cannabis
infused beverages in Canada, with the view of having infused products available
for sale once the regulations permit. </P>
<P align=justify><B>About Hill Street Beverage Co. <BR></B>Founded in 2008, Hill
Street Beverage Co. is the world's most award-winning company exclusively
focused on alcohol-free beer, wines and cocktails. The company offers a wide
range of products including Vin(Zero) wines, Vintense wines, Hill Street Craft
beer, and Designated Draft beer. The company's award-winning products have won
the Retail Council of Canada's Grand Prix, and numerous medals and accolades
including three Gold Medals, two Silvers and one Bronze at the U.S. Open Beer
Championships, and a prestigious Double Gold Medal at the San Francisco
International Wine Challenge. It is expected that Hill Street&#146;s award winning
alcohol-free wines and beers will be available in up to 7,000 stores across
Canada by the end of 2018. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_2></A>
<P align=center>- 2 - </P>
<P align=justify><B>About Lexaria <BR></B>Lexaria Bioscience Corp. has developed
and out-licenses its disruptive delivery technology that promotes healthier
ingestion methods, lower overall dosing and higher effectiveness of lipophilic
active molecules. Lexaria has multiple patents pending in over 40 countries
around the world and has patents granted in the USA and in Australia for
utilization of its DehydraTECH&#153; delivery technology. Lexaria&#146;s technology
provides increases in intestinal absorption rates; more rapid delivery to the
bloodstream; and important taste-masking benefits, for orally administered
bioactive molecules including cannabinoids, vitamins, non-steroidal
anti-inflammatory drugs (NSAIDs), nicotine and other molecules. <BR><U>www.lexariabioscience.com </U></P>
<P><IMG src="tw.jpg" border=0> For regular updates, connect with Lexaria on
Twitter (<U>https://twitter.com/lexariacorp) </U></P>
<P><IMG src="fb.jpg" border=0>&nbsp;and on Facebook <U>http://tinyurl.com/y8vzcaam </U></P>
<P align=justify>FOR FURTHER INFORMATION PLEASE CONTACT:<BR>Lexaria Bioscience
Corp.<BR>Alex Blanchard, Communications Manager <BR>(778) 796-1897 <BR>Or
<BR>NetworkNewsWire (NNW) <BR><U>www.NetworkNewsWire.com
</U><BR>
</P>
<P align=justify>FORWARD-LOOKING STATEMENTS </P>
<P align=justify>This release includes forward-looking statements. Statements
which are not historical facts are forward-looking statements. The Company makes
forward-looking public statements concerning its expected future financial
position, results of operations, cash flows, financing plans, business strategy,
products and services, competitive positions, growth opportunities, plans and
objectives of management for future operations, including statements that
include words such as "anticipate," "if," "believe," "plan," "estimate,"
"expect," &#147;project&#148;, "intend," "may," "could," "should," "will," and other
similar expressions are forward-looking statements, including but not limited
to: that any additional patent protection will be realized or that patent
achievements will deliver material results. Such forward-looking statements are
estimates reflecting the Company's best judgment based upon current information
and involve a number of risks and uncertainties, and there can be no assurance
that other factors will not affect the accuracy of such forward-looking
statements. Factors which could cause actual results to differ materially from
those estimated by the Company include, but are not limited to, government
regulation and regulatory approvals, managing and maintaining growth, the effect
of adverse publicity, litigation, competition, scientific discovery, the patent
application and approval process and other factors which may be identified from
time to time in the Company's public announcements and filings. There is no
assurance that existing capital is sufficient for the Company's needs or that it
will be able to raise additional capital. There is no assurance the Company will
be capable of developing, marketing, licensing, or selling edible products
containing cannabinoids, nicotine or any other active ingredient. There is no
assurance that any planned corporate activity, scientific research or study,
business venture, letter of intent, technology licensing pursuit, patent
application or allowance, consumer study, or any initiative will be pursued, or
if pursued, will be successful. There is no assurance that any of Lexaria&#146;s
postulated uses, benefits, or advantages for the patented and patent-pending
technology will in fact be realized in any manner or in any part. No statement
herein has been evaluated by the Food and Drug Administration (FDA).
Lexaria-associated products are not intended to diagnose, treat, cure or prevent
any disease.</P>
<P align=justify><I>The CSE has not reviewed and does not accept responsibility
for the adequacy or accuracy of this release. </I></P>
<HR align=center width="100%" color=black noShade SIZE=5>
</BODY>

</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>4
<FILENAME>exhibit99-2.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<HTML>
<HEAD>
   <TITLE>Lexaria Bioscience Corp. - Exhibit 99.1 - Filed by newsfilecorp.com</TITLE>
   <META name="HandheldFriendly" content="true">
</HEAD>

<BODY style="font-size:10pt;">

<HR noshade align="center" width=100% size=3 color="black">
<A name=page_1></A>
<P align=right><B>Exhibit 99.2 </B></P>
<P align=center><B>Lexaria Technology Brings &#147;Fast-Acting&#148; to Nuka&#146;s 1906
Cannabis Products with 10-Year </B><BR><B>Deal Consummating Proof-Of-Concept
Relationship</B><BR></P>
<P align=center><I>Nuka&#146;s 1906 chocolates, utilizing Lexaria&#146;s DehydraTECH
technology, have been recognized for </I><BR><I>their fast onset times,
efficacy, amazing taste and unique formulations </I><BR></P>
<P align=justify><B>Kelowna, British Columbia &#150; April 30, 2018</B> &#150; Lexaria
Bioscience Corp. (OTCQX: LXRP) (CSE: LXX), an innovator in drug delivery
platforms, today announced a major new licensing agreement with Nuka Enterprises
LLC, maker of 1906 brand cannabis chocolates and other edible products. The deal
renews Nuka&#146;s DehydraTECH<SUP>TM</SUP> license rights for use in its 1906 brand
of cannabis chocolates<I>, </I>recognized for their fast onset times, efficacy,
amazing taste and unique formulations.</P>
<P align=justify>Nuka has been utilizing Lexaria&#146;s technology within its
award-winning 1906 brand chocolates for nearly two years, during which time 1906
entered the cannabis market; advanced from a start-up to Colorado&#146;s number-three
cannabis chocolate brand available in over 150 locations; and touted by media,
industry watchers and consumers as one of the most innovative brands in the
cannabis space.</P>
<P align=justify>&#147;1906 products are a unique combination of nature and science,
bringing together natural plant medicines delivered in delicious form factors
such as chocolate with advanced technologies that make them safe, predictable,
fast-acting and efficacious,&#148; said Peter Barsoom, CEO of Nuka Enterprises, LLC.
&#147;We&#146;ve worked closely with Lexaria through 1906&#146;s development and launch phases
to create the best possible products that taste great, reduce onset times and
deliver amazing experiences. Fast-acting edibles are the wave of the future -
it's what consumers want - and we are at the forefront of bringing innovations
to address consumer needs.&#148;</P>
<P align=justify>The comprehensive 10-year agreement provides Nuka and 1906 with
competitive technological advantages, as well as growing revenue streams for
Lexaria. The semi-exclusive deal provides Nuka and 1906 with the immediate
ability to utilize DehydraTECH<SUP>TM</SUP> technology across the US. Initially,
1906 will focus on recreational and adult-use states such as Colorado, Nevada,
California, New Jersey, and Massachusetts. Nuka has also acquired an option to
expand its products and brand to Canada, including through the use of Lexaria&#146;s
existing chocolate and confections contract manufacturer licensee Cannfections
Group Inc.</P>
<P align=justify>Nuka and 1906 will leverage the competitive advantages of
DehydraTECH<SUP>TM</SUP> across multiple product lines, as they have also
strategically acquired new rights in product categories in addition to the
original chocolate formats, which include candies, beverages, capsules and
pills, and topical creams. In doing so, Nuka and 1906 have the opportunity to
create America&#146;s first national DehydraTECH<SUP>TM</SUP>-powered cannabis brand
for edible and topical products that offer the superior experiential profiles 1906 consumers desire, together
with the exceptional flavor and speed of onset benefits.</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_2></A>
<P align=justify>&#147;Nuka was our first commercial client and has been an ideal
partner due to their focus on using technology and advanced science as a
competitive advantage,&#148; said Chris Bunka, Chief Executive Officer of Lexaria
Bioscience Corp. &#147;Nuka&#146;s success with the 1906 brand of cannabis chocolates -
recognized for their fast onset times, efficacy, taste and unique formulations &#150;
clearly demonstrate the market potential for DehydraTECH<SUP>TM</SUP>. This
comprehensive, long-term relationship between Nuka and Lexaria is poised to
redefine the cannabis industry and holds great potential for us in other
markets.&#148; </P>
<P align=justify><B>About Nuka Enterprises and 1906 <BR></B>Nuka Enterprises
develops processes, IP and services, focused on disrupting the nascent and fast
emerging cannabis industry. Nuka&#146;s 1906 brand is creating a new category of
premium edibles, marrying the benefits of cacao, cannabis and ethnobotanical
ingredients, designed to appeal to responsible, informed, health conscious
adults. Products that deliver absolutely safe, consistent and predictable
experiences, helping customers re-connect with your senses and addressing
different experiences with truly exceptional tastes. For more information,
please visit <BR><U>www.1906newhighs.com </U></P>
<P align=justify><B>About Lexaria <BR></B>Lexaria Bioscience Corp. has developed
and out-licenses its disruptive delivery technology that promotes healthier
ingestion methods, lower overall dosing and higher effectiveness of lipophilic
active molecules. Lexaria has multiple patents pending in over 40 countries
around the world and has patents granted in the USA and in Australia for
utilization of its DehydraTECH<SUP>TM </SUP>delivery technology. Lexaria&#146;s
technology provides increases in intestinal absorption rates; more rapid
delivery to the bloodstream; and important taste-masking benefits, for orally
administered bioactive molecules including cannabinoids, vitamins, non-steroidal
anti-inflammatory drugs (NSAIDs), nicotine and other molecules. <BR><U>www.lexariabioscience.com </U></P>
<P><IMG
src="tw.jpg"
border=0> For regular updates, connect with Lexaria on Twitter (<U>https://twitter.com/lexariacorp)
</U><br>
<IMG
src="fb.jpg"
border=0> and on Facebook <U>http://tinyurl.com/y8vzcaam </U></P>
<P align=justify>FOR FURTHER INFORMATION PLEASE CONTACT:<BR>Lexaria Bioscience
Corp.<BR>Alex Blanchard, Communications Manager <BR>(778) 796-1897 <BR>Or
<BR>NetworkNewsWire (NNW) <br>
<U>www.NetworkNewsWire.com </U><BR></P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_3></A>
<P align=justify>FORWARD-LOOKING STATEMENTS </P>
<P align=justify>This release includes forward-looking statements. Statements
which are not historical facts are forward-looking statements. The Company makes
forward-looking public statements concerning its expected future financial
position, results of operations, cash flows, financing plans, business strategy,
products and services, competitive positions, growth opportunities, plans and
objectives of management for future operations, including statements that
include words such as "anticipate," "if," "believe," "plan," "estimate,"
"expect," "intend," "may," "could," "should," "will," and other similar
expressions are forward-looking statements, including but not limited to: that
any additional patent protection will be realized or that patent achievements
will deliver material results. Such forward-looking statements are estimates
reflecting the Company's best judgment based upon current information and
involve a number of risks and uncertainties, and there can be no assurance that
other factors will not affect the accuracy of such forward-looking statements.
Factors which could cause actual results to differ materially from those
estimated by the Company include, but are not limited to, government regulation
and regulatory approvals, managing and maintaining growth, the effect of adverse
publicity, litigation, competition, scientific discovery, the patent application
and approval process and other factors which may be identified from time to time
in the Company's public announcements and filings. There is no assurance that
existing capital is sufficient for the Company's needs or that it will be able
to raise additional capital. There is no assurance the Company will be capable
of developing, marketing, licensing, or selling edible products containing
cannabinoids, nicotine or any other active ingredient. There is no assurance
that any planned corporate activity, scientific research or study, business
venture, letter of intent, technology licensing pursuit, patent application or
allowance, consumer study, or any initiative will be pursued, or if pursued,
will be successful. There is no assurance that any of Lexaria&#146;s postulated uses,
benefits, or advantages for the patented and patent-pending technology will in
fact be realized in any manner or in any part. No statement herein has been
evaluated by the Food and Drug Administration (FDA). Lexaria-associated products
are not intended to diagnose, treat, cure or prevent any disease.</P>
<P align=justify><I>The CSE has not reviewed and does not accept responsibility
for the adequacy or accuracy of this release. </I></P>
<HR align=center width="100%" color=black noShade SIZE=5>
</BODY>

</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>tw.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tw.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!# ! +# X,"A .#0X2$1 3&"@:&!86
M&#$C)1TH.C,]/#DS.#= 2%Q.0$1713<X4&U15U]B9VAG/DUQ>7!D>%QE9V/_
MVP!# 1$2$A@5&"\:&B]C0CA"8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C
M8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V/_P  1"  Z #$# 2(  A$! Q$!_\0
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A45HZTVK7,%A:*=^48B! %4  >@IU+161T6L%%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>fb.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fb.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!# ! +# X,"A .#0X2$1 3&"@:&!86
M&#$C)1TH.C,]/#DS.#= 2%Q.0$1713<X4&U15U]B9VAG/DUQ>7!D>%QE9V/_
MVP!# 1$2$A@5&"\:&B]C0CA"8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C
M8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V/_P  1"  V #,# 2(  A$! Q$!_\0
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M6!0L3'Y1C%0VY83ILSNSQBM913@0OB/3Z*!THK@L=($9&#7F^J6;66H2P$<
MY4^W:O2*SM8TB'4XOF^650=KBM*4^5D3CS(\]&0>M=AXB!'AR$\\%?Y5S5WI
M=Y9.5E@? Z,!D$4V2ZNYX5BDDD=%Z*><5U37-9IF2=MRKTQ6OX9LC=ZFKD9C
MB^8GUJ+3]#O;YUQ$4CSDNW%=QI]A#I]NL,*\#J>Y-35JI*R'"-]2SR**6BN*
CQN%%%%, (!&",CWJ,6\(;<(8P?4**** )**** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
